Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – C-o-group doai
Patent
1993-03-03
1997-02-11
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C-o-group doai
H61K 31045
Patent
active
056021844
ABSTRACT:
The invention provides methods of treating cancer including administering an effective amount of selected terpenes to a mammal having the cancer when the cancer is prostate cancer, colon cancer, astrocytoma, or sarcoma. The terpene is selected from the group consisting of a cyclic monoterpene, a noncyclic monoterpene, a noncyclic sesquiterpene and a noncyclic diterpene. The invention also provides a method of sensitizing a cancer to radiation including administering an effective amount of a terpene to a mammal having the cancer wherein the terpene is selected from the group noted above. Additionally, the invention provides methods of inhibiting the growth of cancer cells including applying an effective amount of a selected terpene to the cancer cells which are cells of prostate cancer, colon cancer, osteosarcoma, or glioblastoma.
REFERENCES:
patent: 5243094 (1993-09-01), Borg
Crowell, P. L., et al., "Human metabolism of orally administered d-limonene," Proc. Amer. Assoc. Cancer Res., vol. 33, p. 524, No. 3134 (Mar. 1992).
Crowell, P. L., et al., "Selective Inhibition of Isoprenylation of 21-26-kDa Proteins by the Anticarcinogen d-Limonene and Its Metabolites," J. Biol. Chem. 266(26):17679-17685 (Sep. 15, 1991).
Elegbede, J. A., et al., "Regression of Rat Primary Mammary Tumors Following Dietary d-Limonene," JNCI 76(2):323-325 (Feb. 1986).
Wattenberg. L. W., et al., "Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone carcinogenesis in mice by D-limonene and citrus fruit oils," Carcinogenesis 12(1):115-117 (1991).
"d-Limonene, an Anticarcinogenic Terpene," Nutrition Reviews 46(10):363-365 (Oct. 1988).
Elson, C. E., et al., "Anti-carcinogenic activity of d-limonene during the initiation and promotion/progression stages of DMBA-induced rat mammary carcinogenesis," Carcinogenesis 9(2):331-332 (1988).
Webb, D. R., et al., "Assessment of the Subchronic Oral Toxicity of d-Limonene in Dogs," Fd Chem. Toxic 28(10):669-675 (1990).
Maltzman, T. R. et al., "The prevention of nitrosomethylurea-induced mammary tumors by d-limonene and orange oil," Carcinogenesis 10(4):781-783 (19890.
Carter, B. S., et al., "ras Gene Mutations in Human Prostate Cancer," Cancer Research 50:6830-3832 (Nov. 1, 1990).
Isaacs, W. B., et al., "Genetic Changes Associated with Prostate Cancer in Humans," Cancer Surveys vol. 11 (Prostate Cancer), 15-24 (1991).
Casey, P. J., et al., "p21ras is modified by a farnesyl isoprenoid," Proc. Natl. Acad. Sci. USA 86:8323-8327 (Nov., 1989).
Curt Gregory
Miller Alexandra
Myers Charles E.
Samid Dvorit
Sausville Edward
Goldberg Jerome D.
The United States of America as represented by Department of Hea
LandOfFree
Monoterpenes, sesquiterpenes and diterpenes as cancer therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoterpenes, sesquiterpenes and diterpenes as cancer therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoterpenes, sesquiterpenes and diterpenes as cancer therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-342733